Approved indications: Intravenous amphotericin B deoxycholate is used for severe systemic and disseminated fungal infections caused by susceptible organisms, including Candida, Aspergillus, Cryptococcus (e.g., cryptococcal meningitis), Mucorales (mucormycosis), certain endemic fungi (such as Histoplasma, Coccidioides, Blastomyces), and for fungal infections of sites such as the bloodstream, lungs, brain/meninges, and heart valves.

Off-label uses and evidence: It is used off-label for visceral leishmaniasis where liposomal amphotericin B is not available, for step-in or salvage therapy in refractory invasive mycoses, and sometimes for prophylaxis or preemptive treatment in profoundly immunocompromised patients; these uses are based on clinical experience, observational data, and guideline recommendations rather than dedicated large randomized trials for the conventional formulation.

Efficacy expectations: In severe infections, fever and other symptoms often start to improve within several days, but full treatment courses usually last weeks to months depending on the site and host immune status. Amphotericin B achieves high microbiologic response and cure rates in many life-threatening fungal infections, especially when started early and combined with source control (e.g., surgery, device removal). Compared with newer azoles and echinocandins, it is at least as potent and often preferred for the most severe, rapidly progressive, or central nervous system infections, but its use is limited by higher toxicity, so many patients are switched to an oral azole once stable.

Typical dosing and administration: For most serious systemic fungal infections, amphotericin B deoxycholate is started at about 0.25–0.3 mg/kg/day intravenously and then increased to 0.5–1 mg/kg/day (up to 1.5 mg/kg/day in select life-threatening infections), given once daily as a dilute infusion over 2–4 hours; dosing in neonates and children is weight-based and similar, with adjustments for tolerance and organ function. It is administered in a hospital or specialized infusion setting, usually through a central venous line, and is prepared in dextrose (not saline) according to strict compatibility rules.

Special dosing instructions: Many centers give a small test dose before the first full infusion in high-risk patients to assess for severe reactions. Premedications such as acetaminophen, antihistamines, and sometimes corticosteroids or meperidine (for rigors) may be used to reduce infusion-related symptoms. Adequate hydration and regular monitoring of kidney function, electrolytes, blood counts, and clinical status are essential throughout therapy, and doses may be reduced or held if toxicity develops.

Missed dose and overdose: Because amphotericin B is given under direct medical supervision, decisions about any delayed or missed dose are made by the treating team based on infection severity and lab results. Overdose can cause profound kidney injury, severe electrolyte disturbances, and dangerous heart rhythm changes and requires emergency medical care with intensive monitoring and supportive treatment; there is no specific antidote.

Common side effects: Infusion-related reactions are very common, especially with early doses, and include fever, chills/rigors, nausea, vomiting, headache, muscle and joint aches, and changes in blood pressure; these usually occur during or shortly after the infusion and can be moderated with premedications and slower infusion rates. Kidney toxicity (rise in creatinine, decreased urine output) and electrolyte losses, particularly low potassium and magnesium, develop over days to weeks and often require dose adjustment, IV fluids, and electrolyte replacement. Anemia is also common with prolonged therapy.

Serious or rare adverse effects: Severe renal failure, life-threatening low potassium or magnesium leading to muscle weakness or dangerous heart rhythm problems, severe infusion reactions (including chest pain, shortness of breath, or hypotension), allergic/anaphylactoid reactions, liver test abnormalities, and rarely neurologic or hematologic complications can occur and may require stopping the drug and urgent medical care.

Warnings and precautions: Use requires close monitoring in anyone with pre-existing kidney disease, in patients receiving other nephrotoxic drugs (such as aminoglycosides, some antivirals, cisplatin, or calcineurin inhibitors), and in those at risk for electrolyte imbalances or arrhythmias. Amphotericin B is generally considered the treatment of choice for many serious fungal infections in pregnancy when clearly needed, because experience suggests fetal risk is relatively low compared with untreated infection; it should be used with specialist oversight. Data in breastfeeding are limited, but because the drug is poorly absorbed from the gut, systemic exposure in the infant is expected to be low; decisions should be individualized. It is used in all age groups, including premature neonates, with careful dosing and monitoring.

Comparative safety: Conventional amphotericin B has substantially more kidney and infusion-related toxicity than lipid or liposomal amphotericin B formulations and many azoles or echinocandins, so it is usually reserved for situations where its benefits clearly outweigh these risks or when other options are unsuitable.

Side effect reporting and safety updates: Patients and caregivers should promptly tell the treating team about any new or worsening symptoms during infusions or between doses. In the United States, suspected serious adverse reactions can be reported to the FDA MedWatch program, and up-to-date safety information is available through that program and official prescribing information.

Drug and other interactions: Amphotericin B has few classic liver enzyme–mediated (CYP) interactions but has important pharmacodynamic interactions. Concomitant use with other nephrotoxic agents (such as aminoglycoside antibiotics, vancomycin, some antivirals like foscarnet, cisplatin and other chemotherapy agents, cyclosporine, tacrolimus, and high-dose NSAIDs or iodinated contrast) markedly increases the risk of kidney damage. Diuretics, systemic corticosteroids, and other drugs that lower potassium or magnesium can worsen amphotericin-induced electrolyte losses and raise the risk of arrhythmias. Low potassium can increase toxicity from digoxin and may enhance neuromuscular blockade with certain muscle relaxants.

Precautions and conditions requiring caution: Careful risk–benefit assessment is needed in patients with pre-existing renal impairment, significant electrolyte abnormalities, underlying heart rhythm disorders, or concurrent use of multiple nephrotoxic or potassium-wasting drugs. Therapy should be directed by clinicians experienced in managing invasive fungal disease, particularly in transplant recipients, patients with advanced liver or kidney disease, and those in intensive care units.

Monitoring needs: During treatment, patients typically need frequent blood tests, including serum creatinine and blood urea nitrogen (kidney function), electrolytes (especially potassium and magnesium), complete blood count, and sometimes liver tests, as well as periodic electrocardiograms in high-risk individuals to detect QT- or other rhythm changes. Vital signs and symptoms are monitored during each infusion to identify and manage acute reactions promptly.

Q: What is intravenous amphotericin B used for?
A: It is used in hospitals to treat serious, often life-threatening fungal infections that affect the blood, brain, lungs, or other organs, especially in people with weakened immune systems.

Q: How long will I need to receive amphotericin B infusions?
A: Treatment often continues for several weeks and sometimes months, depending on the type and location of the infection and how well your immune system and lab tests recover, and your team may later switch you to an oral antifungal.

Q: Why are the infusions premedicated and given slowly?
A: The drug can cause chills, fever, and other infusion reactions, so it is usually given over a few hours and often with medicines like acetaminophen or antihistamines to make it more tolerable and safer.

Q: How does amphotericin B compare with newer antifungal drugs?
A: Amphotericin B is one of the most potent broad-spectrum antifungals and is often chosen for the sickest patients, but it causes more kidney and infusion-related side effects than many azoles or echinocandins, so other drugs are used when they are likely to be effective and better tolerated.

Q: Is amphotericin B safe in pregnancy or breastfeeding?
A: When a serious fungal infection is present, amphotericin B is generally preferred in pregnancy because experience suggests it is relatively safe for the fetus compared with alternatives, and it can sometimes be used during breastfeeding under specialist supervision with close monitoring of both mother and baby.